Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis

Overview of attention for article published in Rheumatology International, December 2004

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (81st percentile)
Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

policy: 2 policy sources

Citations

dimensions_citation: 17 Dimensions

Readers on

mendeley: 28 Mendeley

Summary Policy documents Dimensions citations

So far, Altmetric has seen 2 policy documents that reference this research output.

Bisphosphonate Drugs for the Treatment of Osteoporosis in Post-Menopausal Women

Cited by Canadian Agency for Drugs and Technologies in Health on 01 Jun 2021

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Bisphosphonates for treating osteoporosis: Committee papers

Cited by National Institute for Health and Care Excellence on 03 Jul 2017

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.